As with other cancers, AML develops when genetic changes to cells cause them to replicate uncontrollably. In people with secondary AML, these changes occur in immature myeloid blood cells due to ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

which is traditionally treated with a stem-cell transplant. Around 5,500 people are diagnosed with DLBCL in the UK each year, ...

Auron will present acute myeloid leukemia (AML) cell line-based activity, as well as ex vivo and in vivo patient derived xenograft data from AUTX-703, its oral, potent and selective degrader targeting ...

Disclosed on November 13, Neena M Patil, EVP & Chief Legal Officer at Jazz Pharmaceuticals JAZZ -2.13% Get Free Report , ...

Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in ...

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

Aileen Lamb, who was given the all clear after fighting acute myeloid leukaemia, was welcomed the approval of Axicabtagene ciloleucel (axi-cel). The drug is used for adults diagnosed with diffuse ...

Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at ...

For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...